SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001851734-22-000740
Filing Date
2022-12-21
Accepted
2022-12-21 08:30:18
Documents
16
Period of Report
2022-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20221220_8k.htm   iXBRL 8-K 44110
2 EXHIBIT 2.1 ex_458079.htm EX-2.1 597741
3 EXHIBIT 99.1 ex_458080.htm EX-99.1 14922
8 logo.jpg GRAPHIC 2565
  Complete submission text file 0001851734-22-000740.txt   923189

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20221220.xsd EX-101.SCH 3602
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20221220_def.xml EX-101.DEF 11533
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20221220_lab.xml EX-101.LAB 15415
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20221220_pre.xml EX-101.PRE 11689
10 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20221220_8k_htm.xml XML 2593
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 221476613
SIC: 2834 Pharmaceutical Preparations